Firefly Neuroscience stock surges 47.7% on AI-powered ADHD subtype diagnosis breakthrough

Why Firefly Neuroscience Stock Is Soaring Today - Firefly Neuroscience (NASDAQ:AIFF)

Firefly Neuroscience stock is surging to new heights today. Why is AIFF stock surging? Firefly Advances Objective Brain-Based ADHD Diagnosis Tools According to Firefly, the work uses Resting EEG and Cognitive EEG, also known as ERP, to identify potential neural biomarkers tied to hyperactive-impulsive, inattentive and combined ADHD presentations. The announcement is significant because ADHD is typically diagnosed using symptom-based assessments rather than objective biological tools. Firefly said its approach could eventually complement traditional checklists with brain-based data, helping clinicians tailor treatment choices, guide dosage decisions and monitor whether a therapy is working at the neurological level. Firefly Targets $10 Billion U.S. ADHD Treatment Market Management added that the biomarker discovery underscores the company's push to use AI-powered brain analytics to improve diagnosis and treatment monitoring across neurological and psychiatric conditions. AIFF RSI Surges Into Overbought Territory Firefly Neuroscience's RSI has recently surged above 70, indicating the stock has entered overbought territory following a sharp upward move. Over the past year, AIFF's RSI mostly fluctuated within the neutral range (30-70) with occasional dips into oversold levels before the latest spike. AIFF Surges Friday Afternoon AIFF Price Action: Firefly Neuroscience shares were up 47.70% at $2.57 at the time of publication on Friday, according to Benzinga Pro data. Image: Shutterstock This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Firefly Neuroscience stock surges on ADHD subtype research By Investing.com

Investing.com -- Firefly Neuroscience Inc (NASDAQ:AIFF) shares jumped 47.7% Friday following the company's announcement of research advancements using its AI-powered EEG/ERP technology to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder. The company said its FDA-510(k)-cleared Evoke System collected Resting EEG/Cognitive EEG brain scans that may help identify which ADHD subtype a patient has: hyperactive and impulsive, inattentive, or combined. ADHD represents a U.S. treatment market estimated at over $10 billion. The technology aims to complement subjective symptom checklists with neural signal-based precision, potentially helping clinicians determine appropriate treatment types, inform dosage decisions, and monitor whether interventions are working. Over 22 million Americans are diagnosed with ADHD, yet an objective biological marker for distinguishing between its subtypes has remained elusive. Firefly's methodology is supported by prior peer-reviewed research, including a study published in Frontiers in Psychiatry demonstrating the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients. Gil Issachar, Chief Technology Officer of Firefly, commented, "Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans. We believe that the technology also opens the door to ongoing treatment monitoring -- allowing clinicians to objectively track whether an intervention is working at the neurological level." The breakthrough advances Firefly's mission to build the world's first EEG/ERP brain foundation model, being trained on a repository of over 191,000 brain scans. The company has access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.